ASSESSMENT OF PREVALENCE AND PERSISTENCE OF HUMAN PAPILLOMA- VIRUS (HPV) DNA IN

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。人类免疫缺陷病毒（HIV）感染是人类乳头瘤病毒（HPV）感染和女性生殖道HPV相关病变发展的重要风险因素。在对照临床试验的基础上已经确定：1）感染艾滋病毒的妇女发生宫颈发育不良的可能性约为5倍（即，鳞状上皮内瘤变）;和2）在HIV感染的妇女中，在宫颈阴道灌洗液（CVL）或阴道宫颈拭子中检测到HPV DNA的频率是从HIV阴性妇女获得的标本中检测到HPV DNA的频率的2 - 5倍。这些发现表明，HIV感染和/或HIV相关的免疫抑制增加了女性对HPV感染的易感性或改变了先前存在的HPV感染的自然史。目前尚不清楚有效的抗逆转录病毒治疗是否会影响HPV感染的持续性和宫颈发育不良的进展。据推测，生殖道免疫监视的恢复将延缓持续性HPV感染的建立，但这只能通过前瞻性监测一组记录生殖器HPV感染多年的受试者来确定。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Human Immunodeficiency Virus (HIV) Infections is a significant risk factor for Human Papillomavirus (HPV) infection and the development of HPV-associated lesions in the female genital tract. It has been established on the basis of controlled clinical trials that: 1)HIV-infected women are approximately five times as likely to experience cervical dysplasia (i.e., squamous intraepithelial neoplasia) as HIV- negative women: and 2) in HIV-infected women, HPV DNA can be detected in cervicovaginal lavage fluid (CVL) or on vaginal cervical swabs two to five times as frequently as in specimens obtained from HIV- negative women. These findings suggest that HIV infection and/or HIV-related immunosuppression increase a women's susceptibility to HPV infection or alter the natural history of preexisting HPV infection. It is not known whether treatment will potent antiretroviral regimens could affect the persistence of HPV infection and progression of cervical dysplasia. Presumably, restoration of restoration of immune surveillance in the genital tract would retard the establishment of persistent HPV infection, but this can only be determined by prospectively monitoring a group of subjects with documented genital HPV infection over a period of years.